Market Exclusive

UNILIFE CORPORATION (NASDAQ:UNIS) Files An 8-K Regulation FD Disclosure

UNILIFE CORPORATION (NASDAQ:UNIS) Files An 8-K Regulation FD Disclosure

Item 7.01.

Regulation FD Disclosure.

On December 15, 2016, following the conclusion of the annual
stockholders meeting of Unilife Corporation, John Ryan will
provide the remarks attached to this report as Exhibit 99.1 (the
Stockholder Presentation).

The information hereunder shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be incorporated by reference into a
filing under the Securities Act of 1933, or the Exchange Act,
except as shall be expressly set forth by specific reference in
such a filing.

Forward-Looking Statements

This report contains forward-looking statements. All statements
that address operating performance, events or developments that
we expect or anticipate will occur in the future are
forward-looking statements. These forward-looking statements are
based on managements beliefs and assumptions and on information
currently available to our management. Our management believes
that these forward-looking statements are reasonable as and when
made. However, you should not place undue reliance on any such
forward-looking statements because such statements speak only as
of the date when made. We do not undertake any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise,
except as required by law. In addition, forward-looking
statements are subject to certain risks and uncertainties that
could cause actual results, events and developments to differ
materially from our historical experience and our present
expectations or projections. These risks and uncertainties
include, but are not limited to, those described in Item 1A. Risk
Factors and elsewhere in our Annual Report on Form 10-K, those
described in the Risk Factors set forth in our prospectus
supplement, dated as of and filed with the SEC on February 22,
2016, those described from time to time in other reports which we
file with the SEC, and other risks and uncertainties including,
without limitation: that the Companys focus on wearable injector
programs with key pharmaceutical customers may not be successful
and/or result in the commercialization of the Companys products.

Item 9.01.

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit Number

Description

99.1

Unilife Corporation Stockholder Presentation.

2

About UNILIFE CORPORATION (NASDAQ:UNIS)

Exit mobile version